Updated on 4 May 2012
Dr Wu Ke, President - Shanghai BravoBio
China-based start-up company Shanghai BravoBio is dedicated to developing new types of human vaccines to fight against emerging infectious diseases and meet the demand of increasing quality of life. Besides, BravoBio also has plans and potential to explore other diagnostics and therapeutic macro-molecules, for instance monoclonal antibodies (mAbs), fusion proteins, among others.
Shanghai BravoBio was established in March 2011 by Dr Wu Ke along with a team that has more than 20 years of experience in process and method development, cell culture optimization, antigen purification, formulation, sterile filling and packaging.
The management has a strong and effective network in the biotech industry, both in public and private sectors. Hence, inspite of being a young company, BravoBio has knowledge of quality control, quality assurance, pre-clinical and clinical planning, regulatory submissions and inspections, management and operations under GMP, engineering, facility evaluation, maintenance, as well as marketing and post-marketing surveillance.
"All members of BravoBio's management come from the same biotech company. As colleagues, they share a common dream which was restrained in the former framework, so they decided to set up a platform of their own to make the dream come true," says Dr Wu Ke, founder and president, who has 23 years of experience in biopharma industry and has successfully developed seven products approved by the SFDA and marketed in China.
As a self-funded start-up, BravoBio is seeking potential investors who share the same value. But before capital flow-in, BravoBio had already set up two joint ventures with different partners, one with a national biopharmaceuticals marketing company, another with a top institute of China Academy of Sciences.
In the coming years, BravoBio will keep collaborating with strategic partners and expand its business to R&D of proprietary vaccines, diagnostic kits and mAbs; manufacturing and marketing of propriety and generic vaccines and kits; international trading, including technology, patents, bulk and final brand products of biopharmaceuticals.